Findings Could Lead to Early Diagnosis, Better Treatment Studies
An ultrasensitive test has been developed that detects a corrupted protein associated with Alzheimer’s disease and chronic traumatic encephalopathy (CTE), a condition found in athletes, military veterans, and others with a history of repetitive brain trauma. This advance could lead to early diagnosis of these conditions and open new research into how they originate, according to National Institutes of Health scientists and their colleagues. In their new study, published in Acta Neuropathologica, the researchers explain how they adapted a diagnostic test originally developed for prion diseases to detect abnormal clusters of tau protein. Like other proteins involved in neurological diseases, tau protein clusters can seed themselves and contribute substantially to the disease processes of Alzheimer’s and CTE. The study involved brain samples from 16 Alzheimer’s patients, two boxers with CTE, and numerous control cases involving other brain diseases.
The test is extremely sensitive. For example, if a pinhead-sized sample of brain tissue from an Alzheimer’s patient were pulverized and diluted into a thousand gallons of liquid, the test still could detect tau seeds in a pinhead-sized volume of that dilution. The test is called AD RT-QuIC: Alzheimer’s disease real-time quaking induced conversion.
Scientists at NIH’s National Institute of Allergy and Infectious Diseases developed RT-QuIC about a decade ago to detect Creutzfeldt-Jakob (CJD) and other prion diseases. Since then, they have repeatedly improved and adapted it to detect other neurological diseases, such as Parkinson’s and dementia with Lewy bodies. The test, which already is used in clinical settings to diagnose sporadic CJD, is noted for its rapid and accurate results.
Their latest findings could be a major advance for Alzheimer’s diagnostics because the study points to tau seeds as potential biological “markers” for Alzheimer’s disease in the brain. Scientists are testing therapies to slow the accumulation of tau clusters and the progression of neurological disease. In these efforts, they need more sensitive and accurate tests to better select clinical trial participants and assess whether new therapeutic strategies work as hoped.
Alzheimer’s affects about 5.7 million people in the United States alone at an estimated annual cost of $232 billion, according to the Alzheimer’s Association.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Navigating Alzheimer’s during the holiday seasonon December 4, 2021 at 1:30 am
While holidays can be a joyous time for many families, they can be challenging for families affected by Alzheimer’s or another form of dementia. The Alzheimer’s Association’s Western ...
- Santa Fe memory care advocate Jytte Lokvig brings creativity to Alzheimer’s patientson December 3, 2021 at 7:45 pm
Jytte Lokvig at the Santa Fe Children’s Museum where she hosts the Alzheimer Cafe which she established over ten years ago. Lokvig has authored numerous books on caregiving and living with dementia — ...
- University of Iowa study: Alzheimer’s patients more likely to die from COVIDon December 3, 2021 at 3:33 pm
Patients with Alzheimer ’s disease appear to be more likely to die from COVID-19 than those who don’t have the neurodegenerative disease, according to new University of Iowa research that could hold ...
- Bernie Sanders Asks Biden to Prevent Medicare Premium Hike Tied to Pricey Alzheimer's Drugon December 3, 2021 at 1:54 pm
The premium increase is so Medicare will have a reserve prepared if the program formally grants coverage for the drug Aduhelm, Medicare said.
- Sanders urges Biden to delay Medicare premium hike linked to Alzheimer's drugon December 3, 2021 at 1:40 pm
Sen. Bernie Sanders (I-Vt.) is calling on the Biden administration to delay an increase in Medicare premiums for 2022 that is tied in part to a controversial, pricey Alzheimer's drug.In a letter sent ...
- 1950s-themed senior centers are providing comfort for people with Alzheimer’son December 3, 2021 at 12:29 pm
One in nine people over the age of 65 have some form of Alzheimer’s, and the disease is only becoming more prevalent, according to the Alzheimer’s Association. There’s no cure for Alzheimer’s, but ...
- Alzheimer’s Association discusses new antibody infusion drug to help people with the diseaseon December 3, 2021 at 10:48 am
A new drug approved in June by the FDA is offering some hope to those with Alzheimer's Disease and other neurodegenerative disorders. Dr. Percy Griffin is Director of Scientific Engagement with the ...
- Walk to End Alzheimer's Intern (unpaid)on December 3, 2021 at 10:25 am
Hours per week minimum Be part of the movement to end Alzheimer’s! Right now, millions of Americans are facing ...
- As Medicare Decides Whether To Pay For Aduhelm To Treat Alzheimer’s Disease, Its Future Is Uncertainon December 3, 2021 at 6:25 am
CMS has embarked on a national coverage determination process, in which it's examining the clinical safety and benefit profile of Aduhelm and other anti beta amyloid monoclonal antibodies in Alzheimer ...
- Biogen's Spinraza, Fosun-Kite's Yescarta and a controversial Alzheimer's drug: All you need to know about China's new state coverageon December 3, 2021 at 6:15 am
Sixty-seven novel therapies entered China’s national reimbursement drug list for the first time and offered an average 61.7% discount through negotiations with the government. Here we summarize some ...
via Bing News